REC Ref.	IRAS No.	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
16/WS/0005	193858	A PHASE 3, LONG-TERM ACTIVE TREATMENT EXTENSION STUDY OF MONGERSEN (GED-0301) IN SUBJECTS WITH CROHN?S DISEASE	Number Agreed	2	2	Date Agreed	01/11/2021	0	21/12/2017	0	Withdrawn By Sponsor
15/NE/0389	194347	Phase 1 study to assess Single Doses of ABY-035 in Healthy Subjects and Psoriasis Patients	Number Agreed	3	3	Date Agreed	01/02/2018	3	01/02/2018	3	Recruitment Finished
16/ES/0001	193859	A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of Mongersen (GED-0301) for the treatment of subjects with active Crohn?s disease	Number Agreed	2	2	Date Agreed	31/07/2017	1	31/07/2017	1	Recruitment Finished
16/LO/0351	190075	A double blind, randomized placebo controlled crossover multiple dose study of LJN452 to assess safety, tolerability and efficacy in patients with primary bile acid diarrhea (pBAD)	Number Agreed	7	7	Date Agreed	16/11/2017	7	07/02/2018	9	Recruitment Finished
14/NW/1427	166630	A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson?s Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control	Number Agreed	4	4	Date Agreed	13/12/2017	6	24/07/2017	6	Recruitment Finished
17/LO/0783	225826	A Multicenter, Parallel-Group, Randomized, Cross-Over Trial to Compare the Efficacy of LUMINITY? and SonoVue? in the Evaluation of Left Ventricular Endocardial Border Definition	Number Agreed	4	4	Date Agreed	14/05/2018	0	21/03/2018	0	Withdrawn By Sponsor
17/EM/0005	215706	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction	Number Agreed	15	15	Date Agreed	05/01/2020	0	29/01/2018	0	Withdrawn By Sponsor
16/SC/0422	209437	A PHASE 2A STUDY OF TRC105 (WITH OPTION TO ADD STANDARD DOSE BEVACIZUMAB) IN PATIENTS WITH REFRACTORY GESTATIONAL TROPHOBLASTIC NEOPLASIA (GTN)	Number Agreed	2	2	Date Agreed	01/05/2018	0	31/07/2017	0	Withdrawn By Sponsor
16/NE/0084	196157	A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (nal-IRI)-containing Regimens versus Gemcitabine plus nab-Paclitaxel in Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma	Number Agreed	2	2	Not Available / Not Agreed			18/04/2018	0	Withdrawn By Sponsor
16/YH/0004	190267	A Phase II, Single Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of MOR00208 Combined with Idelalisib in Patients with Relapsed or Refractory CLL/SLL Previously Treated with Bruton?s Tyrosine Kinase (BTK) Inhibitor	Range Agreed	1	2	Date Agreed	29/01/2021	0	07/11/2017	0	Recruitment Finished
15/WA/0358	189344	An exploratory, open-label, multicenter study to evaluate the safety and efficacy of a two-dose regimen of ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment), in patients with	Number Agreed	2	2	Date Agreed	10/03/2017	2	21/11/2017	3	Recruitment Finished
15/NW/0431	177346	A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR	Number Agreed	2	2	Date Agreed	31/12/2017	1	01/12/2017	1	Recruitment Finished

16/EM/0259	165592	A prospective, multicentre, open-label, randomized, active-controlled, 3 parallel groups, phase 2 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid), versus masitinib alone, versu	Number Agreed	2	2	Date Agreed	22/07/2017	3	22/07/2017	3	Recruitment Finished
15/WM/0327	185434	Clinical evaluation of the Therapeutic IntraVascular Ultrasound (TIVUS?) System for pulmonary artery denervation in patients with pulmonary hypertension	Number Agreed	5	5	Date Agreed	30/06/2017	2	02/10/2017	2	Recruitment Finished
14/SC/0262	151493	A Phase IV, prospective, open-label, uncontrolled, European Study in patients with neovascular Age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching From intravitreal Aflibercept to RanIbizumab 0.5mg: the SAFARI study	Number Agreed	6	6	Date Agreed	30/10/2017	9	14/09/2017	9	Recruitment Finished
16/WM/0271	200160	Prospective, Single-Arm, Multi-Centre Study to Evaluate the Contour Neurovascular System?	Number Agreed	10	10	Date Agreed	07/07/2021	5	27/10/2017	5	Withdrawn By Sponsor
16/EM/0180	199125	A Multicentre Dose-Finding, Randomised, Double-Blind, Placebo-Controlled Study to Select the Daily Oral Dose of Estetrol (E4) for the Treatment of Vasomotor Symptoms in Post-Menopausal Women	Number Agreed	8	8	Date Agreed	21/09/2017	3	29/08/2017	3	Withdrawn By Sponsor
09/H0724/39		Evaluation of Safety and Effectiveness of the FormulaTM PTMTM Balloon-Expandable stent for Renal Artery Stenosis	Not Available / Not Agreed			Not Available / Not Agreed			03/10/2017	0	Recruitment Finished
16/EE/0463	214371	An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced br	Number Agreed	1	1	Date Agreed	31/10/2017	1	07/11/2017	1	Recruitment Finished
16/WM/0433	215494	A research study to describe the ?real world? use of Thrombopoietin-Receptor Agonists (TRAs) in the management of Immune Thrombocytopenia (ITp) in the UK	Number Agreed	20	20	Date Agreed	31/08/2017	39	31/08/2017	39	Recruitment Finished
17/LO/0100	200545	A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens	Number Agreed	3	3	Date Agreed	31/05/2018	0	22/09/2017	0	Withdrawn By Sponsor
16/WM/0250	194366	A prospective, multi-national, multicentre, non-interventional study to evaluate the long term safety of Esmya, in particular the endometrial safety, and the current prescription and management patterns of Esmya in a long term treatment setting.	Number Agreed	10	10	Date Agreed	31/03/2018	4	31/03/2018	4	Withdrawn By Sponsor
16/NW/0728	211957	Investigation of the impact of healthcare professionals advice on the development of good sleep habits in babies under 12 months of age	Not Available / Not Agreed			Not Available / Not Agreed			31/12/2017	0	Recruitment Finished
16/EM/0376	211430	The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cysti	Number Agreed	04/01/1900	04/01/1900	Date Agreed	15/02/2018	0	15/02/2018	0	Recruitment Finished
16/SS/0134	199690	A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY AND DETERMINE THE MAXIMUM TOLERATED DOSE OF PF-05230907 IN SUBJECTS	Number Agreed	03/01/1900	03/01/1900	Date Agreed	28/02/2019	0	02/03/2018	0	Withdrawn By Sponsor
15/LO/2098	182147	A Phase III Double-blind, Randomised, Parallel-Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Moderate or Severe Acute Respiratory Distress Syndrome	Number Agreed	14/01/1900	14/01/1900	Date Agreed	01/02/2018	3	11/12/2017	3	Recruitment Finished
14/NI/0002	143644	AN OPEN LABEL, REGISTRY STUDY OF THE SAFETY OF ILUVIEN? 190 MICROGRAMS INTRAVITREAL IMPLANT IN APPLICATOR	Number Agreed	12/01/1900	12/01/1900	Date Agreed	30/12/2016	12	12/07/2017	12	Recruitment Finished

07/H1102/84		Sunitinib treatment of renal adjuvant cancer (S-TRAC) A randomised double blind phase 3 study of adjuvant vs placebo in subjects at high risk of recurrent RCC. Study Number: A6181109	Number Agreed	03/01/1900	03/01/1900	Not Available / Not Agreed			30/08/2017	0	Recruitment Finished
12/YH/0179	102439	A Companion Trial to Study GS-US-312-0116: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab as Therapy for Patients with Previously Treated Chronic Lymphocyt	Number Agreed	02/01/1900	02/01/1900	Date Agreed	19/11/2017	2	15/02/2018	2	Recruitment Finished
17/NW/0175	222859	A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult patients with Persistent/Chronic Immune Thrombocytopenia	Number Agreed	01/01/1900	01/01/1900	Date Agreed	20/12/2017	2	17/05/2018	2	Recruitment Finished
17/LO/0304	222475	A double-blind, randomised, placebo-controlled, parallel-group, phase 2, dose-ranging trial to evaluate the efficacy, safety and tolerability of oral Litoxetine 10mg, 20mg and 40mg twice daily (BID) versus placebo in women with mixed urinary continence	Range Agreed	10/01/1900	12/01/1900	Date Agreed	31/10/2018	0	31/08/2017	0	Withdrawn By Sponsor
17/EE/0081	219405	An open label, single arm pilot study of OncoSil?, administered to study participants with unresectable locally advanced pancreatic adenocarcinoma, given in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies.	Number Agreed	02/01/1900	02/01/1900	Date Agreed	01/06/2020	17	01/06/2018	17	Recruitment Finished
16/LO/2148	219354	A Multi-Centre, Open Label, Phase IIb Study, Evaluating the Safety, Tolerability and Efficacy of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically Significant, Localised, Low- to Intermediate-Risk Prostate	Number Agreed	04/01/1900	04/01/1900	Date Agreed	01/01/2018	8	01/01/2018	8	Recruitment Finished
16/WM/0006	192580	WHIST - Wound Healing In Surgery for Trauma. A Randomised Controlled Trial of standard wound management versus negative pressure wound therapy in the treatment of adult patients having surgical incisions for major trauma to the lower limb	Number Agreed	11/02/1900	11/02/1900	Date Agreed	30/04/2018	37	30/04/2018	37	Recruitment Finished
14/LO/0344	140294	A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) versus Physician?s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimen	Number Agreed	01/01/1900	01/01/1900	Date Agreed	01/07/2017	2	01/07/2017	2	Recruitment Finished
16/YH/0022	194494	A phase I, multicenter, open-label, single-sequence drugdrug interaction study to assess the effect of INC280 on the pharmacokinetics of midazolam and caffeine in patients with cMET-dysregulated advanced solid tumors	Number Agreed	03/01/1900	03/01/1900	Date Agreed	16/08/2016	0	05/07/2017	0	Recruitment Finished
16/EE/0009	189564	A Phase 3,Randomized,Controlled, Multi-Center,Open-Label,Study To Compare Tivozanib Hydrochloride To Sorafenib In Subjects With Refractory Advanced Renal Cell Carcinoma	Number Agreed	03/01/1900	03/01/1900	Not Available / Not Agreed			11/08/2017	1	Withdrawn By Sponsor
15/LO/1232	182226	Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue	Number Agreed	03/01/1900	03/01/1900	Date Agreed	30/11/2017	7	22/02/2018	7	Recruitment Finished
16/YH/0081	186580	A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis.	Number Agreed	01/01/1900	01/01/1900	Date Agreed	24/04/2018	0	24/04/2018	0	Recruitment Finished
16/NE/0023	190035	A Phase III, Multi-centre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study with Open-Label Extension of Crenezumab in Patients with Prodromal-to-Mild Alzheimer?s Disease	Number Agreed	08/01/1900	08/01/1900	Date Agreed	01/08/2018	8	01/08/2017	8	Recruitment Finished
16/LO/0124	182955	A study of the ReCor Paradise System in Clinical Hypertension	Number Agreed	10/01/1900	10/01/1900	Date Agreed	17/12/2019	10	17/12/2017	10	Recruitment Finished
15/LO/1538	188226	A study to evaluate the effectiveness and safety of Exablate transcranial MRgFUS thalamotomy treatment of medication refractory essential tremor subjects	Number Agreed	10/01/1900	10/01/1900	Date Agreed	13/02/2019	0	16/10/2017	0	Recruitment Finished

15/LO/1641	180563	Global Clinical Study of Renal Denervation with the Symplicity Spyral? multielectrode renal denervation system in Patients with Uncontrolled Hypertension in the Absence of Antihypertensive Medications	Number Agreed	05/01/1900	05/01/1900	Date Agreed	01/11/2019	6	04/06/2018	6	Recruitment Finished
15/LO/1163	181430	A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed on Regimens containing ABC/3TC	Number Agreed	30/01/1900	30/01/1900	Date Agreed	31/12/2017	5	30/03/2018	5	Recruitment Finished
15/LO/1640	180561	Global Clinical Study of Renal Denervation with the Symplicity Spyral? multielectrode renal denervation system in patients with uncontrolled hypertension on standard medical therapy	Number Agreed	05/01/1900	10/01/1900	Date Agreed	31/12/2019	1	03/05/2018	1	Withdrawn By Host
15/LO/0141	169126	The Efficacy and Safety of Bimatoprost SR in Patients With Openangle Glaucoma or Ocular Hypertension	Number Agreed	01/01/1900	01/01/1900	Date Agreed	30/11/2017	1	30/11/2017	1	Recruitment Finished
15/LO/1487	172859	A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer	Number Agreed	03/01/1900	03/01/1900	Date Agreed	01/08/2018	3	01/06/2018	3	Recruitment Finished
15/EM/0021	166923	A randomised, double blind, placebo controlled multicenter trial, examining the effect of Natrox? on the rates of healing for chronic diabetic foot ulcers	Number Agreed	05/01/1900	05/01/1900	Date Agreed	01/08/2017	7	01/08/2017	7	Recruitment Finished
14/LO/1728	158859	A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination with Topotecan (Hycamtin?) in Patients with Solid Tumors	Number Agreed	02/01/1900	02/01/1900	Date Agreed	31/07/2017	2	31/07/2017	2	Recruitment Finished
14/LO/2143	164828	Measurement of low-energy stimulation in patients with atrial fibrillation	Number Agreed	10/01/1900	10/01/1900	Date Agreed	31/08/2017	3	31/08/2017	3	Recruitment Finished
11/EE/0256		Multi-centre, open label, prospective, consecutive series registry database of BioPoly RS Partial Resurfacing Knee implant	Number Agreed	10/01/1900	10/01/1900	Date Agreed	31/12/2016	0	01/06/2018	0	Recruitment Finished
12/NW/0137	98327	A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin	Number Agreed	05/01/1900	05/01/1900	Date Agreed	03/11/2017	5	03/11/2017	5	Recruitment Finished
16/EE/0133	202599	Safety and proof of principle study of ATX-GD-59 in male and female subjects with Graves? disease not currently treated with anti-thyroid therapy: An Open label study, with an upward titration over five dose levels administered by Intradermal injection	Range Agreed	03/01/1900	05/01/1900	Date Agreed	30/01/2018	1	30/01/2018	1	Recruitment Finished
16/LO/0886	204525	A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke	Number Agreed	03/01/1900	03/01/1900	Date Agreed	31/08/2017	7	31/08/2017	7	Recruitment Finished
14/WS/1146	166537	Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients with a recent Embolic Stroke of Undetermined Source (ESUS),	Number Agreed	20/01/1900	20/01/1900	Date Agreed	31/12/2016	20	15/01/2018	27	Recruitment Finished
17/LO/0082	217324	A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of PuraStat Absorbable Haemostatic Material for the Management of Bleeding in Vascular Surgery	Number Agreed	03/01/1900	03/01/1900	Date Agreed	31/12/2017	4	31/12/2017	4	Recruitment Finished
16/LO/0118	191634	Valiant Evo International Clinical Trial	Number Agreed	04/01/1900	04/01/1900	Date Agreed	30/07/2018	5	01/06/2018	5	Recruitment Finished
17/WS/0030	191416	A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	Number Agreed	02/01/1900	02/01/1900	Date Agreed	30/11/2017	4	03/03/2018	4	Recruitment Finished